{"slug":"2026-09","label":"September 2026","volume":27,"number":9,"source_url":"https://medicinetoday.com.au/current-issue","updated_at":"2026-09-18T04:18:29.795Z","articles":[{"id":1,"issue_slug":"2026-09","section":"Feature article","topic":"Immunology and allergy","title":"Updated anaphylaxis guidelines: a summary for primary care","authors":"Katie Frith, Preeti Joshi, Jill Smith, Connie Katelaris, Kristina Rueter","url":"https://medicinetoday.com.au/mt/2026/september/feature-article/updated-anaphylaxis-guidelines-summary-primary-care","pages":null,"cpd":"1.5 h (free access)","summary":"A primary-care digest of ASCIA's 2026 update to its acute anaphylaxis guidelines. The headline messages are unchanged but sharpened: anaphylaxis is a clinical diagnosis, it may present without skin features, and single-system respiratory or cardiovascular involvement counts. Adrenaline is first-line and must not be delayed; IM into the outer mid-thigh remains standard, and intranasal adrenaline (neffy) is now an approved, PBS-listed option for patients aged 4 years and over weighing at least 15 kg. IV adrenaline boluses stay out of the first-line picture outside specialist settings. Positioning is treated as a safety issue in its own right: lie the patient flat (or sitting with legs out if breathing is difficult) and never let them stand or walk. The article also walks through weight-based device selection, supportive care (oxygen, IV fluids for cardiovascular compromise) and the minimum four-hour observation after adrenaline.","key_points":["Hospital admissions and deaths from anaphylaxis in Australia are rising; ASCIA has updated its 2026 acute management guideline, training and action plans.","Adrenaline is first-line and should be given without delay. IM outer mid-thigh is standard; intranasal adrenaline (neffy) is approved for ≥4 years and ≥15 kg.","ASCIA recommends 150 mcg devices for infants and children 7.5–20 kg — this differs from some product information.","PBS-listed devices: EpiPen, Anapen, Jext and (from July 2026) neffy 1 mg / 2 mg by weight and age.","IV adrenaline boluses are not recommended first-line outside specialist settings.","Upright posture increases the risk of a fatal reaction: patients must lie flat and must not stand or walk; observe for at least 4 hours after adrenaline."],"sort_order":0},{"id":2,"issue_slug":"2026-09","section":"Feature article","topic":"Cardiovascular medicine","title":"Targeting inflammation to reduce residual cardiovascular risk – where do we stand in 2026?","authors":"Christian P. Abhayaratna, Nelson Wang, Adam J. Nelson, Walter P. Abhayaratna","url":"https://medicinetoday.com.au/mt/2026/september/feature-article/targeting-inflammation-reduce-residual-cardiovascular-risk-where-do-we-stand-2026","pages":null,"cpd":"1.5 h","summary":"A practical framework for the patient with established atherosclerotic disease whose LDL-C and blood pressure are already at target but who is still at risk. The authors argue that inflammation is an independent, modifiable driver of that residual risk, and that hs-CRP (about $20–60 out of pocket) is the practical marker: a level of 2 mg/L or more on statin therapy defines residual inflammatory risk. The main actionable therapy is low-dose colchicine 0.5 mg daily — off-label in Australia but backed by COLCOT (23% relative reduction in MACE after MI) and LoDoCo2 (31% reduction in stable coronary disease, NNT 35), and now carried in the 2024 ESC, 2023 AHA/ACC and 2025 Australian ACS guidelines. Benefit is for clinically stable patients (generally 6 months or more post-event); CLEAR SYNERGY showed no benefit when started within 72 hours of MI. The article covers who to consider, pre-treatment checks (eGFR, FBC, LFTs), renal cut-offs and CYP3A4/P-gp interactions, and notes that GPs can start colchicine without specialist referral. It closes with a tour of the anti-inflammatory effects of statins, SGLT2 inhibitors, icosapent ethyl and GLP-1 agonists, and the sobering ZEUS result for the IL-6 inhibitor ziltivekimab, which lowered hs-CRP but not events.","key_points":["hs-CRP interpretation: <1 mg/L low, 1–3 intermediate, >3 high; ≥2 mg/L on a statin = residual inflammatory risk. Test in established ASCVD once LDL-C and BP are optimised.","Colchicine 0.5 mg daily (off-label) reduces MACE by 23–31% on top of standard therapy in stable ASCVD; NNT around 35 in LoDoCo2.","Start only in clinically stable patients (≥6 months post-event); no benefit shown when started within 72 h of acute MI.","Avoid if eGFR <30; use with caution and monitoring at eGFR 30–60. Check eGFR, FBC and LFTs before starting and periodically.","Stop colchicine with strong CYP3A4/P-gp inhibitors (clarithromycin, ketoconazole, ritonavir, ciclosporin); review the dose with verapamil, diltiazem or amiodarone.","GI upset occurs in about 10% but only marginally above placebo; small added myopathy risk with high-dose statins or renal impairment.","Ziltivekimab (IL-6 inhibitor) lowered hs-CRP but did not reduce MACE in ZEUS; ARTEMIS (post-MI) is ongoing."],"sort_order":1},{"id":3,"issue_slug":"2026-09","section":"Feature article","topic":"Hepatology","title":"The steatotic liver diseases: a modern clinical perspective","authors":"Harendran Elangovan, Jacob George","url":"https://medicinetoday.com.au/mt/2026/september/feature-article/steatotic-liver-diseases-modern-clinical-perspective","pages":"12–17","cpd":null,"summary":"An update on metabolic dysfunction-associated fatty liver disease (MAFLD) framed as a systemic metabolic condition rather than a liver problem in isolation — cardiovascular disease and extrahepatic cancers, not cirrhosis, are the leading causes of death. The authors want GPs to look beyond BMI (using ethnicity-specific thresholds, type 2 diabetes, metabolic syndrome or a waist-to-height ratio of 0.5 or more as triggers), use ultrasound as the first-line test, and then risk-stratify with a FIB-4 score: below 1.3 can stay in primary care, higher scores go for second-line fibrosis testing and specialist input. Weight loss is still the cornerstone, with graded targets (5% for steatosis, 7–10% for steatohepatitis remission, over 10% for fibrosis regression) supported by a Mediterranean-style diet, 150–240 minutes of aerobic activity a week, resistance training and — pleasingly — regular unsweetened coffee. On drugs, semaglutide 2.4 mg is now TGA-approved for MASH with F2–F3 fibrosis (not PBS-listed) after showing roughly 60% steatohepatitis resolution and 37% fibrosis improvement; tirzepatide is promising but unapproved for this indication, and resmetirom is not available in Australia.","key_points":["MAFLD is diagnosed on metabolic criteria, not BMI alone; screen people with type 2 diabetes, metabolic syndrome or central adiposity (waist-to-height ratio ≥0.5).","Cardiovascular disease and extrahepatic cancers are the main causes of death — manage the whole cardiometabolic picture.","Ultrasound first, then FIB-4: <1.3 = low risk, primary-care follow-up; higher = second-line fibrosis test and specialist confirmation.","Weight-loss targets: 5% reduces steatosis, 7–10% remits steatohepatitis, >10% regresses fibrosis.","Mediterranean-style diet, 150–240 min/week aerobic exercise, resistance training 2–3 times a week, unsweetened coffee; alcohol below ~20 g/day (women) or 30 g/day (men).","Semaglutide 2.4 mg is TGA-approved for MASH with F2–F3 fibrosis but not PBS-listed; tirzepatide and resmetirom are not yet available for this use in Australia.","Histological fibrosis reversal has not yet been proven to improve hard liver outcomes — treatment rests on surrogate markers and mechanism."],"sort_order":2},{"id":4,"issue_slug":"2026-09","section":"Regular series","topic":"Psychological medicine","title":"Brain fog and menopause: practical management in primary care","authors":"Caroline Gurvich, Marita Long","url":"https://medicinetoday.com.au/mt/2026/september/regular-series/brain-fog-and-menopause-practical-management-primary-care","pages":null,"cpd":null,"summary":"About two in three women notice cognitive change through perimenopause — memory lapses, word-finding trouble, mental fatigue — and this piece gives GPs a reassuring but structured way to handle it. Subjective complaints usually outstrip any objective decline, the symptoms are typically transient, and they are not a sign of dementia. Contributors are multiple: hormonal shifts, poor sleep, mood, normal ageing and midlife load. Assessment should validate the symptoms while excluding other causes; management is really about brain health in general — screen for and treat sleep disorders (CBT for insomnia first-line), push physical activity to 150–300 minutes of moderate or 75–150 minutes of vigorous exercise weekly plus strength work twice a week, tighten vascular risk factors (systolic BP 130 mmHg or below, lipids, smoking, glucose), and teach external memory aids. Menopausal hormone therapy has no overall effect on objective cognition or long-term dementia risk, although some women report feeling clearer on it.","key_points":["Cognitive symptoms affect roughly two-thirds of perimenopausal women, are usually transient and do not indicate dementia.","Subjective complaints generally exceed objective decline; assessment should acknowledge symptoms and rule out other diagnoses.","Sleep: screen for sleep disorders; CBT for insomnia is first-line.","Exercise: 150–300 min moderate or 75–150 min vigorous aerobic activity per week plus muscle-strengthening twice weekly.","Vascular health: systolic BP ≤130 mmHg, lipid control, smoking cessation, glucose monitoring.","MHT does not change objective cognition or dementia risk overall, though some women report subjective improvement."],"sort_order":3},{"id":5,"issue_slug":"2026-09","section":"Regular series","topic":"Women's health","title":"Unscheduled bleeding on menopausal hormone therapy: when to investigate, adjust or reassure","authors":"Talat Uppal, Sneha Wadhwani","url":"https://medicinetoday.com.au/mt/2026/september/regular-series/unscheduled-bleeding-menopausal-hormone-therapy-when-investigate-adjust-or-reassure","pages":"38–45","cpd":null,"summary":"Unscheduled bleeding hits up to 40% of women starting or changing menopausal hormone therapy and is a leading reason they stop. The authors' central point is that bleeding on MHT is not the same clinical entity as postmenopausal bleeding off treatment, and needs its own algorithm. Bleeding within six months of starting or three months of a dose change can be watched if it is not heavy, prolonged or persistent and the woman's endometrial cancer risk is low. Investigate when bleeding falls outside those windows, is heavy or persistent, when cancer risk factors are present, or when examination is abnormal — transvaginal ultrasound is the first-line test, with reassuring endometrial thickness cut-offs of 4 mm or less on continuous combined regimens and 7 mm or less on sequential ones. Often the fix is pharmacological rather than diagnostic: check adherence, adjust the dose, and make sure the progestogen component is actually protecting the endometrium before escalating.","key_points":["Up to 40% of women bleed when starting or changing MHT; most episodes are benign but the approach differs from postmenopausal bleeding in non-users.","Expected windows: within 6 months of starting, or 3 months after a dose change — observe if not heavy, prolonged or persistent and cancer risk is low.","Investigate bleeding outside those windows, heavy or persistent bleeding, significant cancer risk factors, or abnormal examination.","Transvaginal ultrasound is first-line: endometrial thickness ≤4 mm (continuous combined) or ≤7 mm (sequential) is reassuring.","Before escalating, review adherence, consider dose adjustment and confirm the progestogen gives adequate endometrial protection."],"sort_order":4},{"id":6,"issue_slug":"2026-09","section":"Regular series","topic":"Paediatrics clinic","title":"ADHD in children – practical clinical pearls for GPs","authors":"Catherine McHugh, Alison Poulton, Valsamma Eapen","url":"https://medicinetoday.com.au/mt/2026/september/regular-series/adhd-children-%E2%80%93-practical-clinical-pearls-gps","pages":"47–53","cpd":null,"summary":"A pearls-style guide to the GP's role in childhood ADHD, which affects an estimated 6–10% of Australian children. The authors stress that ADHD is a functional diagnosis — symptoms must impair the child in more than one setting and be read against developmental stage — and that comorbidity is the rule (87% have at least one other condition, commonly learning disorders, anxiety, mood problems, sleep issues or tics). Assessment is multi-informant (parents, school, the adolescent), uses validated scales (Vanderbilt, SDQ or SNAP-IV), and includes hearing, vision, neurological examination, sleep, nutrition and baseline height, weight, BMI, BP and heart rate. Management is multimodal: parent and family training is the primary treatment under five, with sleep and lifestyle work, CBT for impaired adolescents, social-skills training and school liaison alongside. Stimulants (methylphenidate, lisdexamfetamine, dexamfetamine) are first-line from age five, with atomoxetine, guanfacine or clonidine as alternatives; prescribing rules vary by state. Reviews should track two or three concrete functional goals, growth and cardiovascular parameters, mood and sleep, with red flags for affective switching, weight loss, worsening mood or psychosis.","key_points":["Interpret symptoms developmentally — what is abnormal at 14 may be normal at 4; impairment must be present in more than one setting.","Comorbidity is the rule (87%): actively look for learning disorders, anxiety, mood difficulties, sleep problems and tics.","Use validated scales (Vanderbilt, SDQ, SNAP-IV) and information from parents and school; examine hearing, vision, neurology, sleep, growth, BP and heart rate.","Parent/family training is the primary treatment under 5 years; CBT for adolescents builds compensatory skills rather than curing the condition.","Stimulants are first-line from age 5; atomoxetine, guanfacine or clonidine if contraindicated or ineffective. State prescribing rules differ.","Review against 2–3 documented functional goals; monitor height, weight, BMI, BP, HR, sleep and mood; at least 6-monthly when stable.","Red flags for another or coexisting diagnosis: sudden onset, regression, focal neurology, severe mood symptoms, or symptoms in only one setting."],"sort_order":5},{"id":7,"issue_slug":"2026-09","section":"Regular series","topic":"Travel medicine update","title":"Genetics, genomics and travel health","authors":"Jonathan Cohen","url":"https://medicinetoday.com.au/mt/2026/september/regular-series/genetics-genomics-and-travel-health","pages":"55–57","cpd":null,"summary":"A short update on where genetic and molecular testing already earns its place in travel medicine, and where it does not yet. Three tests are in routine use: G6PD status must be confirmed before prescribing primaquine or tafenoquine for terminal malaria prophylaxis because of haemolysis risk; travellers with a personal or strong family history of venous thromboembolism warrant a thrombophilia screen (factor V Leiden and prothrombin variants markedly raise long-haul flight risk); and returning travellers with diarrhoea should have a faecal multiplex PCR requested alongside conventional microscopy. Pharmacogenomic testing, altitude-illness genetics and genomic antimicrobial-resistance surveillance are flagged as promising but not ready for the pretravel consultation.","key_points":["Use the pretravel consultation to identify patients whose genetics raise their risk of travel illness or adverse drug reactions.","Confirm normal G6PD status before prescribing tafenoquine or primaquine.","Request coagulation/thrombophilia screening for travellers with prior VTE or a strong family history.","For travellers' diarrhoea, order stool microscopy and a faecal multiplex PCR.","Pharmacogenomic tests currently add little in travel medicine; tailored genomic advice is a future prospect."],"sort_order":6},{"id":8,"issue_slug":"2026-09","section":"Regular series","topic":"Dermatology clinic","title":"A young woman with a facial papulopustular eruption","authors":"Elyssa Chee, Niyaz Mostafa, Esther Hong","url":"https://medicinetoday.com.au/mt/2026/september/regular-series/young-woman-facial-papulopustular-eruption","pages":"58–61","cpd":null,"summary":"A case-based dermatology clinic: a 25-year-old lawyer with six months of tender papules and pustules on the cheeks, chin and forehead, flaring with stress, exercise and her cycle, and unresponsive to over-the-counter salicylic acid and benzoyl peroxide. Examination shows inflammatory papules and pustules plus open and closed comedones with post-inflammatory pigmentation but no nodules or cysts. The presence of comedones is the decisive clue — it separates acne vulgaris from periorificial dermatitis, rosacea, folliculitis (bacterial or Malassezia), acneiform drug eruptions and follicular occlusion disorders. Persistent adult acne in a woman prompted screening for PCOS, which was confirmed. She was started on a combined oral contraceptive and switched to a nightly clindamycin–benzoyl peroxide fixed combination, with review at six weeks.","key_points":["Comedones are the hallmark lesion that distinguishes acne vulgaris from its mimics (periorificial dermatitis, rosacea, folliculitis, drug eruptions).","Take a thorough history: onset, cosmetics, medications, family history and menstrual pattern.","Topical therapy for mild acne; oral therapy (including a combined oral contraceptive where appropriate) for moderate to severe or hormonally driven acne.","Screen women with persistent acne for polycystic ovary syndrome."],"sort_order":7},{"id":9,"issue_slug":"2026-09","section":"In brief","topic":"Women's health","title":"PMOS associated with increased risk of cardiovascular disease","authors":null,"url":"https://medicinetoday.com.au/mt/2026/september/in-brief/pmos-associated-increased-risk-cardiovascular%C2%A0disease","pages":null,"cpd":null,"summary":"A US insurance-claims cohort in The Lancet Obstetrics, Gynaecology & Women's Health followed 413,000 women aged 18–50 with polyendocrine metabolic ovarian syndrome (PMOS, the condition formerly known as PCOS) against more than two million matched controls over 2000–2022. Women with PMOS had roughly four times the rate of atherosclerotic cardiovascular events (adjusted HR 4.4; 4.5 vs 0.8 events per 1000 person-years over a mean 3.5 years). Hypertension, dyslipidaemia, type 2 diabetes and obesity explained only about a third of the excess. Professor Amanda Henry (George Institute, UNSW) commented that the remaining two-thirds points to the pathophysiology of PMOS itself driving cardiovascular risk — an argument for treating PMOS as a cardiovascular risk enhancer in its own right.","key_points":["Adjusted HR 4.4 for ASCVD events in women with PMOS vs matched controls; absolute rates 4.5 vs 0.8 per 1000 person-years.","Traditional risk factors account for only about a third of the association.","Consider PMOS/PCOS a cardiovascular risk enhancer when assessing younger women."],"sort_order":8},{"id":10,"issue_slug":"2026-09","section":"In brief","topic":"Endocrinology","title":"Primary hyperparathyroidism: end-organ damage common, surgery underused, finds study","authors":null,"url":"https://medicinetoday.com.au/mt/2026/september/in-brief/primary-hyperparathyroidism-endorgan-damage-common-surgery-underused-finds-study","pages":null,"cpd":null,"summary":"A JAMA Surgery cohort of 43,399 US adults (mean age 68, 78% women) with a new biochemical diagnosis of primary hyperparathyroidism between 2010 and 2023 found that two-thirds had skeletal or renal end-organ damage either at diagnosis or during follow-up. Just over half already had damage when diagnosed — most commonly CKD stage 3 or worse (73% of those affected), then kidney stones (21%), osteoporosis (21%) and fragility fractures (12%) — and a further 32% of the remainder developed it within a median of 17 months. Despite that, only one in five patients with end-organ damage went on to parathyroidectomy. Brisbane endocrinologist Dr Elizabeth Wootton's comment for GPs: we probably do not take primary hyperparathyroidism seriously enough, and every new diagnosis should be worked up for end-organ damage with bone density, renal imaging and urine calcium.","key_points":["66% of patients had skeletal or kidney end-organ damage at diagnosis or during follow-up; 51% at diagnosis.","Only about 20% of those with end-organ damage had a parathyroidectomy.","Work up every new diagnosis: DXA, renal imaging for stones, eGFR and urine calcium — and refer for surgery where criteria are met."],"sort_order":9},{"id":11,"issue_slug":"2026-09","section":"In brief","topic":"Dermatology","title":"Routine antihistamines offer little benefit for eczema","authors":null,"url":"https://medicinetoday.com.au/mt/2026/september/in-brief/routine-antihistamines-offer-little-benefit-eczema","pages":null,"cpd":null,"summary":"A BMJ systematic review and network meta-analysis of 47 randomised trials (6230 children and adults, mostly with moderate to severe atopic dermatitis) found that adding oral H1 antihistamines to background therapy produced only trivial reductions in eczema and itch severity — well short of clinically meaningful thresholds — with no improvement in sleep disturbance or flares on low-certainty evidence. First-generation agents carried a real cost: 66 extra cases of cognitive impairment per 1000 patients. Second-generation agents varied, from none with loratadine to around 16–17 per 1000 with levocetirizine and cetirizine. Associate Professor Stephen Shumack noted that antihistamines no longer feature in modern national or international atopic dermatitis guidelines and are worth considering only where urticaria coexists.","key_points":["H1 antihistamines add little to eczema or itch control and do not improve sleep or exacerbations.","First-generation (sedating) antihistamines cause cognitive impairment in about 66 more patients per 1000 with no meaningful benefit.","Reserve antihistamines for eczema patients who also have urticaria; treat the eczema itself with guideline-based therapy."],"sort_order":10},{"id":12,"issue_slug":"2026-09","section":"In brief","topic":"Paediatrics","title":"First Australian guideline on childhood hypertension","authors":null,"url":"https://medicinetoday.com.au/mt/2026/september/in-brief/first-australian-guideline-childhood-hypertension","pages":null,"cpd":null,"summary":"Australia now has its first national guideline on hypertension in children, published in the Journal of Paediatrics and Child Health by the BPOzKids Network and Hypertension Australia with Heart Foundation endorsement. For children without risk factors it recommends blood-pressure screening at 7–9 years and again at 13–15; at-risk children (obesity, stimulant medication) should have BP checked at every visit from age three. Simplified screening thresholds are 120/80 mmHg for ages 6–11 and 130/85 mmHg for ages 12–17, using a validated automated oscillometric device, with diagnosis confirmed on three separate auscultatory measurements and ambulatory monitoring before treatment to exclude white-coat hypertension. First-line management is a six-month trial of team-based lifestyle change — salt reduction, a DASH-style diet and 120–150 minutes of moderate-to-vigorous activity a week — with long-acting calcium-channel blockers or ACE inhibitors/ARBs if drugs are needed. Lead author Dr Nicholas Larkins notes prevalence is rising and childhood BP tracks to adult cardiac and kidney events.","key_points":["Screen all children at 7–9 and 13–15 years; at-risk children (obesity, stimulants) at every visit from age 3.","Screening thresholds: 120/80 mmHg (6–11 years) and 130/85 mmHg (12–17 years) on a validated oscillometric device.","Confirm with three auscultatory readings and ambulatory BP monitoring before treating.","Six months of team-based lifestyle management first; then long-acting CCB or ACE inhibitor/ARB."],"sort_order":11},{"id":13,"issue_slug":"2026-09","section":"In brief","topic":"Diabetes","title":"Sarcopenic obesity linked to greater type 2 diabetes risk than either condition alone","authors":null,"url":"https://medicinetoday.com.au/mt/2026/september/in-brief/sarcopenic-obesity-linked-greater-type-2-diabetes-risk-either-condition-alone","pages":null,"cpd":null,"summary":"A prospective UK Biobank analysis in Diabetes Care of 479,607 adults without diabetes at baseline classified participants by handgrip strength, muscle-mass-to-weight ratio and fat percentage into neither condition, obesity alone, sarcopenia alone or sarcopenic obesity. Over a median 14 years, 32,948 developed type 2 diabetes. Sarcopenic obesity carried a 3.5-fold hazard versus neither condition — 19% higher than obesity alone and 91% higher than sarcopenia alone — with 10-year cumulative incidence of 14.9% compared with 10.6%, 7.7% and 3.2% respectively. The association was stronger in women and in adults under 60. The authors' practical suggestion for primary care is to add a handgrip strength measurement to routine diabetes risk assessment rather than relying on BMI alone, given skeletal muscle's central role in insulin-mediated glucose disposal.","key_points":["Sarcopenic obesity: HR 3.54 for incident type 2 diabetes vs neither condition; 10-year incidence 14.9%.","Risk exceeds obesity alone by 19% and sarcopenia alone by 91%; associations stronger in women and under-60s.","Consider adding handgrip strength to diabetes risk assessment alongside BMI."],"sort_order":12},{"id":14,"issue_slug":"2026-09","section":"In brief","topic":"Mental health","title":"Marked increase in mental health disorders among Australian youth","authors":null,"url":"https://medicinetoday.com.au/mt/2026/september/in-brief/marked-increase-mental-health-disorders-among-australian-youth","pages":null,"cpd":null,"summary":"Comparing the 2007 and 2020–22 waves of the Australian National Study of Mental Health and Wellbeing, using identical diagnostic interviews, researchers writing in The Lancet Regional Health – Western Pacific found the 12-month prevalence of any mental disorder among 16–24-year-olds rose from 23.4% to 36.2%. Anxiety disorders more than doubled (12.2% to 29.1%) and mood disorders nearly tripled (4.9% to 13.3%), while substance use disorders fell (12.3% to 7.8%). Severe cases climbed from 14.7% to 24.0%, young people were 2.4 times more likely to be in the higher-severity band, and one in five now has more than one disorder (one in ten in 2007). Dr Louise Birrell of the Matilda Centre recommends routine mental health assessment in this age group and early help-seeking.","key_points":["12-month prevalence of any mental disorder in 16–24-year-olds: 23.4% (2007) → 36.2% (2020–22).","Anxiety 12.2% → 29.1%; mood disorders 4.9% → 13.3%; substance use disorders fell 12.3% → 7.8%.","Severe cases and comorbidity have risen sharply — consider routine mental health screening of young adults."],"sort_order":13},{"id":15,"issue_slug":"2026-09","section":"Newsbite","topic":"Urology","title":"New prostate cancer guidelines","authors":null,"url":"https://medicinetoday.com.au/mt/2026/september/in-brief/new-prostate-cancer-guidelines","pages":null,"cpd":null,"summary":"The Prostate Cancer Foundation of Australia's 2026 Clinical Practice Guidelines for the Early Detection of Prostate Cancer, approved by the NHMRC, set a national framework for risk assessment, shared decision-making, PSA testing and the diagnostic pathway, with the stated aim of finding clinically significant cancer earlier while cutting unnecessary testing and treatment. The full guideline is available as a PDF from the PCFA website.","key_points":["NHMRC-approved 2026 PCFA guideline covering risk assessment, shared decision-making, PSA testing and diagnosis.","Goal: earlier detection of clinically significant prostate cancer with fewer unnecessary tests and treatments."],"sort_order":14},{"id":16,"issue_slug":"2026-09","section":"Newsbite","topic":"Women's health","title":"Hospital care for endometriosis","authors":null,"url":"https://medicinetoday.com.au/mt/2026/september/in-brief/hospital-care-endometriosis","pages":null,"cpd":null,"summary":"An AIHW report on endometriosis hospital procedures shows admissions for endometriosis rose 23% over the past decade, against a 5% rise in all female hospitalisations. There were 24,700 admissions in 2024–25, more than 90% involving a procedure — most often diagnostic procedures, IUD insertion and laparoscopy. Admissions without a procedure grew from 6% to 9% over the decade, which the AIHW reads as improved access to advanced pain management.","key_points":["Endometriosis admissions up 23% in ten years; 24,700 admissions in 2024–25, >90% with a procedure.","Non-procedural admissions rising (6% → 9%), reflecting greater access to advanced pain management."],"sort_order":15},{"id":17,"issue_slug":"2026-09","section":"Newsbite","topic":"Correction","title":"Correction: residual risk in atherosclerotic cardiovascular disease (July 2026)","authors":null,"url":"https://medicinetoday.com.au/mt/2026/september/in-brief/correction","pages":null,"cpd":null,"summary":"A correction to the July 2026 feature 'Residual risk in atherosclerotic cardiovascular disease: a clinical overview' (Nguyen, Marathe, Psaltis; pages 10–20). The hypertriglyceridaemia section on page 14 wrongly stated that icosapent ethyl is PBS-subsidised for reducing cardiovascular risk in patients with ASCVD, type 2 diabetes or both. Icosapent ethyl is TGA-approved for statin-treated patients with elevated triglycerides and either established cardiovascular disease or diabetes with additional risk factors, but PBS subsidy is limited to patients with established atherosclerotic cardiovascular disease and hypertriglyceridaemia — narrower than the TGA indication.","key_points":["Icosapent ethyl PBS subsidy is restricted to established ASCVD with hypertriglyceridaemia; the diabetes-without-ASCVD group is TGA-approved but not PBS-subsidised."],"sort_order":16}]}